lanreotidi
Lanreotide, sometimes referred to as lanreotidi in some languages, is a long-acting somatostatin analog used in the treatment of acromegaly and certain neuroendocrine tumors. It is a peptide drug that forms a sustained-release depot after deep subcutaneous injection, typically administered every 28 days.
Lanreotide works by binding somatostatin receptors, predominantly sst2 and sst5, on pituitary and neuroendocrine tumor cells.
Common indications include the treatment of adults with acromegaly who require medical therapy to control hormone
Dosing is tailored to the individual and the indication. Typical regimens involve 60 mg every 28 days
Common adverse effects include gastrointestinal symptoms (diarrhea, abdominal pain, nausea), injection-site reactions, and gallbladder changes such
Lanreotide has been marketed under brand names such as Somatuline Depot and Lanreotide Autogel and is produced